X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PANACEA BIOTECH - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PANACEA BIOTECH ASTRAZENECA PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 119.9 134.6 89.1% View Chart
P/BV x 17.1 3.0 571.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PANACEA BIOTECH
Mar-14
ASTRAZENECA PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,285149 864.2%   
Low Rs63482 770.4%   
Sales per share (Unadj.) Rs189.684.1 225.3%  
Earnings per share (Unadj.) Rs-0.2-18.3 1.1%  
Cash flow per share (Unadj.) Rs3.8-6.7 -57.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.683.7 82.0%  
Shares outstanding (eoy) m25.0061.25 40.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.4 368.7%   
Avg P/E ratio x-4,712.7-6.3 74,696.6%  
P/CF ratio (eoy) x249.6-17.2 -1,447.5%  
Price / Book Value ratio x14.01.4 1,013.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9887,074 339.1%   
No. of employees `0001.62.8 56.7%   
Total wages/salary Rs m1,6051,449 110.7%   
Avg. sales/employee Rs Th3,040.21,874.1 162.2%   
Avg. wages/employee Rs Th1,029.2527.0 195.3%   
Avg. net profit/employee Rs Th-3.3-407.7 0.8%   
INCOME DATA
Net Sales Rs m4,7405,154 92.0%  
Other income Rs m92100 92.3%   
Total revenues Rs m4,8325,254 92.0%   
Gross profit Rs m-130-766 16.9%  
Depreciation Rs m101711 14.2%   
Interest Rs m01,503 0.0%   
Profit before tax Rs m-139-2,881 4.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m1391,771 7.8%   
Tax Rs m517 30.3%   
Profit after tax Rs m-5-1,121 0.5%  
Gross profit margin %-2.7-14.9 18.4%  
Effective tax rate %-3.7-0.6 628.3%   
Net profit margin %-0.1-21.8 0.5%  
BALANCE SHEET DATA
Current assets Rs m2,7263,810 71.6%   
Current liabilities Rs m2,4358,365 29.1%   
Net working cap to sales %6.1-88.4 -7.0%  
Current ratio x1.10.5 245.8%  
Inventory Days Days74156 47.4%  
Debtors Days Days4167 60.6%  
Net fixed assets Rs m1,03514,480 7.1%   
Share capital Rs m5061 81.6%   
"Free" reserves Rs m942903 104.4%   
Net worth Rs m1,7165,127 33.5%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m4,15619,433 21.4%  
Interest coverage xNM-0.9-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.10.3 430.0%   
Return on assets %-0.12.0 -6.2%  
Return on equity %-0.3-21.9 1.4%  
Return on capital %03.6 0.0%  
Exports to sales %5.724.5 23.2%   
Imports to sales %6.510.2 63.5%   
Exports (fob) Rs m2701,264 21.4%   
Imports (cif) Rs m306525 58.4%   
Fx inflow Rs m3751,539 24.3%   
Fx outflow Rs m470942 49.9%   
Net fx Rs m-96597 -16.0%   
CASH FLOW
From Operations Rs m-8599 -1.4%  
From Investments Rs m-146-438 33.3%  
From Financial Activity Rs m862-303 -284.9%  
Net Cashflow Rs m709-141 -501.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.6 50.0%  
FIIs % 15.7 1.3 1,207.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.6 38.6%  
Shareholders   12,856 10,259 125.3%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 20, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS